Tema Heart & Health ETF (NASDAQ:HRTS) Shares Up 0.2% – Should You Buy?

Tema Heart & Health ETF (NASDAQ:HRTS)’s stock price shot up 0.2% during trading on Thursday . The stock traded as high as $36.95 and last traded at $36.80. 3,298 shares traded hands during trading, a decline of 48% from the average session volume of 6,325 shares. The stock had previously closed at $36.72.

Tema Heart & Health ETF Stock Up 0.2%

The company’s 50 day simple moving average is $35.65 and its 200-day simple moving average is $34.91. The firm has a market cap of $54.83 million, a P/E ratio of 22.06 and a beta of 0.63.

Institutional Investors Weigh In On Tema Heart & Health ETF

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada boosted its holdings in Tema Heart & Health ETF by 8.8% during the 1st quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock valued at $710,000 after acquiring an additional 1,703 shares during the period. Kestra Advisory Services LLC purchased a new stake in Tema Heart & Health ETF in the fourth quarter worth $27,000. Stifel Financial Corp lifted its position in shares of Tema Heart & Health ETF by 19.8% during the fourth quarter. Stifel Financial Corp now owns 33,647 shares of the company’s stock worth $1,187,000 after purchasing an additional 5,571 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Tema Heart & Health ETF during the third quarter worth $243,000. Finally, Jane Street Group LLC boosted its stake in shares of Tema Heart & Health ETF by 9.4% during the second quarter. Jane Street Group LLC now owns 37,164 shares of the company’s stock valued at $1,062,000 after purchasing an additional 3,202 shares during the period.

Tema Heart & Health ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.